3 reports of this reaction
11.1% of all STRYCHNOS IGNATII SEED reports
#5 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #5 most commonly reported adverse reaction for STRYCHNOS IGNATII SEED, manufactured by Aurobindo Pharma Limited. There are 3 FDA adverse event reports linking STRYCHNOS IGNATII SEED to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 11.1% of all 27 adverse event reports for this drug.
Patients taking STRYCHNOS IGNATII SEED who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a frequently reported adverse event for STRYCHNOS IGNATII SEED, accounting for a significant proportion of all reports.
In addition to white blood cell count decreased, the following adverse reactions have been reported for STRYCHNOS IGNATII SEED:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 3 FDA reports for STRYCHNOS IGNATII SEED. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 11.1% of all adverse event reports for STRYCHNOS IGNATII SEED, making it a notable side effect.
If you experience white blood cell count decreased while taking STRYCHNOS IGNATII SEED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.